Lupin will pay US$150 million to resolve antitrust litigation over its alleged role in a scheme to delay generic versions of the blockbuster diabetes treatment Glumetza, 10 days after Bausch Health settled for US$300 million, according to a federal court filing in San Francisco.
The drug distributors leading part of the lawsuit sought preliminary approval for the deal late Monday, September 20, from Judge William Alsup, who’s overseeing the consolidated case in the US District Court for the Northern District of California, where a trial of “direct purchaser” claims is set to start October 4.
Glumetza, an extended-release form of metformin hydrochloride, was approved by the Food and Drug Administration (FDA) in 2005, originally sold by Depomed, now called Assertio. Depomed marketed the drug in partnership with Santarus, which was later acquired by Bausch.
In 2009, Lupin applied to the FDA to make a generic version of the drug, and Depomed sued. In 2012, the companies reached a settlement in which Lupin agreed to delay launch of its product until 2016, and Depomed agreed to pay Lupin’s legal fees and not to offer its own so-called authorized generic that would compete with Lupin’s during Lupin’s legally mandated 180-day period of market exclusivity.
In their 2019 lawsuit, the Glumetza purchasers allege that arrangement was an illegal “reverse payment” or “pay-for-delay” settlement, which courts have held can violate federal antitrust laws. They said Depomed later reached settlements with other generic companies to delay competing products as well, though they are not named as defendants.
The purchasers claim that the illegal monopoly allowed Bausch, then known as Valeant Pharmaceuticals, to hike the drug’s price by 800% in 2015. Though generic versions have since come on the market, prices remain higher than they would be without the 2012 settlement, the purchasers say.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FCC Set to Reinstate Net Neutrality Rules Today
Apr 25, 2024 by
CPI
Chamber of Commerce Sues to Overturn FTC Non-Compete Ban
Apr 24, 2024 by
CPI
FTC Chief Warns of Healthcare Price Fixing Risks Amid Tech Advancements
Apr 24, 2024 by
CPI
Amazon’s Investment in Anthropic Faces Antitrust Scrutiny
Apr 24, 2024 by
CPI
Italian Antitrust Authority Fines Amazon €10 Million for Unfair Trade Practices
Apr 24, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI